GAITHERSBURG, Md.--(BUSINESS WIRE)--Ore Pharmaceuticals Inc. (NASDAQ: ORXE) today announced that it has completed dosing volunteer subjects in its multiple ascending dose clinical study of the Company’s lead drug candidate, GL1001. The study, initiated in September, was a blinded, placebo-controlled study in 32 healthy volunteers which studied multiple ascending doses up through the highest planned dose of 1800mg. The compound was orally administered once daily for 14 days. All of the dose levels were well tolerated and no serious adverse events were observed in any of the study cohorts. Biomarker results from the study will be the subject of a future presentation in 1Q 2009. The findings from this study, combined with anticipated results from in-vivo toxicology studies currently underway, are expected to support the Company’s conduct of future proof-of-concept clinical studies.
